ARNUITY ELLIPTA
ICS DPI
Fluticasone furoate · GlaxoSmithKline
Active Medication & Mechanism
- Fluticasone furoate ICS50 mcg, 100 mcg, or 200 mcg per blister
Synthetic trifluorinated corticosteroid with potent anti-inflammatory activity and enhanced glucocorticoid receptor affinity. Once-daily dosing due to prolonged retention in lung tissue.
FDA-Approved Dosing — Strength × Indication
Strength Regimen AsthmaCOPD
100 mcg
1 inhalation once daily → 100 mcg
FDA Approved
For patients previously requiring medium-dose inhaled corticosteroids.
Not Approved
Arnuity Ellipta is not indicated for COPD.
200 mcg
1 inhalation once daily → 200 mcg
FDA Approved
For patients previously requiring high-dose inhaled corticosteroids.
Not Approved
Arnuity Ellipta is not indicated for COPD.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
100 mcg 1 inhalation once daily → 100 mcg
Asthma FDA Approved
For patients previously requiring medium-dose inhaled corticosteroids.
COPD Not Approved
Arnuity Ellipta is not indicated for COPD.
200 mcg 1 inhalation once daily → 200 mcg
Asthma FDA Approved
For patients previously requiring high-dose inhaled corticosteroids.
COPD Not Approved
Arnuity Ellipta is not indicated for COPD.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute use. Use a SABA.